Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4122676 | 0.86 | CYP4F2 (0.40) | DGAT1CYP4F2CYP4A11TSHR | |
| SCHEMBL2022397 | 0.85 | DGAT1 (0.44) | DGAT1CYP4F2CYP4A11ELANETSHR | |
| SCHEMBL4650865 | 0.85 | CYP4F2 (0.43) | DGAT1CYP4F2CYP4A11ELANETSHR | |
| SCHEMBL9129151 | 0.83 | CYP4F2 (0.46) | DGAT1CYP4F2CYP4A11ELANETSHR | |
| SCHEMBL8986987 | 0.83 | CYP4F2 (0.46) | DGAT1CYP4F2CYP4A11ELANETSHR | |
| SCHEMBL8987098 | 0.83 | CYP4F2 (0.46) | DGAT1CYP4F2CYP4A11ELANETSHR | |
| SCHEMBL116575 | 0.80 | — | — | |
| SCHEMBL3041732 | 0.79 | DGAT1 (0.41) | DGAT1CYP4F2CYP4A11ELANE | |
| SCHEMBL18982744 | 0.79 | DGAT1 (0.33) | DGAT1CYP4F2CYP4A11TSHR | |
| SCHEMBL1798350 | 0.78 | ELANE (0.47) | DGAT1CYP4F2CYP4A11ELANETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288683-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-18 | — | — | US | disclosed |
| US-20250084044-A1 | PROTOPORPHYRINOGEN OXIDASE INHIBITORS | ENKO CHEM, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| EP-4519272-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20240383886-A1 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | ABBVIE INC. | 2024-11-21 | — | — | US | disclosed |
| CN-118541030-A | Protoporphyrinogen oxidase inhibitors | 恩科化学公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-112384509-B | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023215449-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-11795149-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795149-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-4055602-A | PROSTAGLANDIN | THE UPJOHN COMPANY (US) | 1977-10-25 | — | — | US | disclosed |
| US-4054737-A | Thromboxane B analogs | THE UPJOHN COMPANY (US) | 1977-10-18 | — | — | US | disclosed |
| US-4033949-A | Analogs of thromboxane B2 and processes for their synthesis | THE UPJOHN COMPANY (US) | 1977-07-05 | — | — | US | disclosed |
| US-4033989-A | 9-Deoxy-PGF2 Analogs | THE UPJOHN COMPANY (US) | 1977-07-05 | — | — | US | disclosed |
| US-4029681-A | 13,14-Didehydro-PG analogs | THE UPJOHN COMPANY (US) | 1977-06-14 | — | — | US | disclosed |
| US-4028419-A | PROSTAGLANDINS | THE UPJOIN COMPANY (US) | 1977-06-07 | — | — | US | disclosed |
| US-4026909-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1977-05-31 | — | — | US | disclosed |
| US-4018803-A | 13,14-Didehydro-PG3 compounds | THE UPJOHN COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
| US-4016184-A | PROSTAGLANDINS, BLOOD PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1977-04-05 | — | — | US | disclosed |
| US-3931279-A | 5-Oxa prostaglandin F2.sub.α analogs | THE UPJOHN COMPANY (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084044-A1 | PROTOPORPHYRINOGEN OXIDASE INHIBITORS | PPOX, CYP4X1, PNPO | DGAT1 3851/4885CYP4F2 40/4885CYP4A11 188/4885 |
| US-20240383886-A1 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | PTPN5, PTPN1, PTPN2 | DGAT1 2933/4885CYP4F2 1937/4885CYP4A11 2702/4885 |
| US-11795149-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | IDO1, INMT, IRF3 | DGAT1 1923/4885CYP4F2 2675/4885CYP4A11 1659/4885 |
| US-20250288683-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2L1, BCL2, BCL2L10 | DGAT1 3243/4885CYP4F2 3328/4885CYP4A11 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.